Finward Bancorp Bio N Tech Se Call Options Transaction History
Finward Bancorp
- $127 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNTX
# of Institutions
320Shares Held
40.9MCall Options Held
1.38MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$853 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$449 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$424 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$382 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$201 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...